During a live event, John S. Renshaw, MD, and other oncologists discussed various trials of novel regimens for patients with ...

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for patients with blood cancers.

President Donald J. Trump has signaled that lowering the costs of prescription drugs will be a priority for his second term.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Deborah Wong, MD, PhD, discussed the role of PD-1 inhibitors in nasopharyngeal cancer and their ...

Panelists discuss how risk stratification, symptom burden, and splenomegaly guide treatment decisions for a 68-year-old woman with intermediate-risk myelofibrosis who isn’t interested in transplant.

Panelists discuss how JAK inhibitor therapy can benefit patients with intermediate-1–risk myelofibrosis despite being studied primarily in higher-risk patients in the COMFORT and JUMP trials.

A panelist discusses how to sequence the four approved cGVHD agents based on patient-specific factors, recommending exotilimab or belumosidil for lung involvement, any of the three oral agents for ...

During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy ...

Marwan G. Fakih, MD, discusses topics in metastatic colorectal cancer from the Case-Based Roundtable meeting he moderated.

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

Investigators also explored the combined impact of diet and physical activity. The findings indicate that the best survival outcomes were among patients who engaged in higher levels of physical ...